论文部分内容阅读
目的:探讨托拉塞米联合人血白蛋白治疗肝硬化腹水的临床疗效。方法:将2014年8月至2016年3月怀集县人民医院收治的70例肝硬化腹水患者随机分成观察组与对照组各35例。在常规治疗的基础上,观察组予托拉塞米联合人血白蛋白治疗,对照组患者仅予托拉塞米治疗,疗程均为1周。比较两组患者腹胀缓解时间、腹水减退时间和每日尿量,以及治疗后血清Na+和K+浓度的变化。结果:观察组腹胀缓解时间及腹水减退时间均明显少于对照组,分别为[(3.1±1.5)d vs(4.5±1.3)d,(4.2±1.8)d vs(6.1±2.3)d,均P<0.05];观察组每日平均尿量明显多于对照组[(2137.4±252.6)ml vs(1529.6±217.3)ml,P<0.05]。两组治疗后的血清Na+和K+浓度无明显差异(均P>0.05)。结论:托拉塞米和人血白蛋白联合应用治疗肝硬化腹水能够起到协同增效的作用,提高临床治疗效果。
Objective: To investigate the clinical efficacy of torsemide combined with human serum albumin in the treatment of ascites due to cirrhosis. Methods: Seventy patients with cirrhosis and ascites admitted to Huaiji County People’s Hospital from August 2014 to March 2016 were randomly divided into observation group (35 cases) and control group (35 cases). On the basis of routine treatment, the observation group received torsemide combined with human serum albumin, while the control group received only torsemide, the course of treatment was 1 week. The duration of abdominal distension, ascites drop time and daily urine output in both groups were compared, and the changes of serum Na + and K + concentrations after treatment were compared. Results: The time to relieve abdominal distension and the time to ascites in observation group were significantly less than those in control group [(3.1 ± 1.5) d vs (4.5 ± 1.3) days vs (4.2 ± 1.8 days vs 6.1 ± 2.3 days, respectively P <0.05]. The daily average urine volume in the observation group was significantly higher than that in the control group [(2137.4 ± 252.6) ml vs (1529.6 ± 217.3) ml, P <0.05]. There was no significant difference between the two groups in serum Na + and K + concentrations (all P> 0.05). Conclusion: The combination of torsemide and human serum albumin in the treatment of cirrhosis and ascites can play a synergistic effect and improve the clinical curative effect.